Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
Summers, 1999
Ho, 2001, Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era, Perspect Biol Med, 44, 1, 10.1353/pbm.2001.0006
Sulakvelidze, 2001, Bacteriophage therapy, Antimicrob Agents Chemother, 45, 649, 10.1128/AAC.45.3.649-659.2001
Slopek, 1987, Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986, Arch Immunol Ther Exp, 35, 569
Alisky, 1998, Bacteriophages show promise as antimicrobial agents, J Infect, 36, 5, 10.1016/S0163-4453(98)92874-2
Weber-Dabrowska, 2000, Bacteriophage therapy of bacterial infections: an update of our institute's experience, Arch Immunol Ther Exp, 48, 547
Chanishvili, 2002
1983, Phage therapy [editorial], Lancet, 2, 1287
Lederberg, 1996, Smaller fleas ad infinitum: therapeutic bacteriophage redux, Proc Natl Acad Sci USA, 93, 3617, 10.1073/pnas.93.8.3167
Barrow, 1997, Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential, Trends Microbiol, 5, 268, 10.1016/S0966-842X(97)01054-8
Carlton, 1999, Phage therapy: past history and future prospects, Arch Immunol Ther Exp, 5, 267
Pirisi, 2000, Phage therapy-advantages over antibiotics?, Lancet, 356, 1418, 10.1016/S0140-6736(05)74059-9
Das, 2001, Bacteriophage therapy offers new hope for streptococcal infections, Lancet, 357, 938, 10.1016/S0140-6736(05)71639-1
Stone, 2002, Bacteriophage therapy. Stalin's forgotten cure, Science, 298, 728, 10.1126/science.298.5594.728
Merril, 2003, The prospect for bacteriophage therapy in Western medicine, Nat Rev Drug Discov, 2, 489, 10.1038/nrd1111
Thacker, 2003, Set a microbe to kill a microbe: drug resistance renews interest in phage therapy, JAMA, 290, 3183, 10.1001/jama.290.24.3183
Bradbury, 2004, “My enemy's enemy is my friend.” Using phages to fight bacteria, Lancet, 363, 624, 10.1016/S0140-6736(04)15629-8
Levin, 2004, Population and evolutionary dynamics of phage therapy, Nat Rev Microbiol, 2, 166, 10.1038/nrmicro822
Ackermann, 1987
Ackermann, 2001, Frequency of morphological phage descriptions in the year 2000, Arch Virol, 146, 843, 10.1007/s007050170120
Matsuzaki, 1998, Cloning and sequencing of major capsid protein (mcp) gene of a vibriophage, KVP20, possibly related to T-even coliphages, Gene (Amst), 222, 25, 10.1016/S0378-1119(98)00459-4
Matsuzaki, 1992, A broad-host-range vibriophage, KVP40, isolated from sea water, Microbiol Immunol, 36, 93, 10.1111/j.1348-0421.1992.tb01645.x
Matsuzaki, 1992, Evidence for the existence of a restriction-modification system common to several species of the family Vibrionaceae, FEMS Microbiol Lett, 94, 191, 10.1111/j.1574-6968.1992.tb05313.x
Inoue, 1995, A 26-kDa outer membrane protein, OmpK, common to Vibrio species is the receptor for a broad-host-range vibriophage, KVP40, FEMS Microbiol Lett, 125, 101, 10.1111/j.1574-6968.1995.tb07342.x
Inoue, 1995, Cloning and sequence analysis of Vibrio parahaemolyticus ompK gene encoding a 26-kDa outer membrane protein, OmpK, that serves as receptor for a broad-host-range vibriophage, KVP40, FEMS Microbiol Lett, 134, 245, 10.1111/j.1574-6968.1995.tb07945.x
Matsuzaki, 1998, A vibriophage, KVP40, with major capsid protein homologous to gp23* of coliphage T4, Virology, 242, 314, 10.1006/viro.1997.9018
Matsuzaki, 1999, Major capsid proteins of certain Vibrio and Aeromonas phages are homologous to the equivalent protein, gp23*, of coliphage T4, Arch Virol, 144, 1647, 10.1007/s007050050618
Matsuzaki, 1999, Vibriophage KVP40 and coliphage T4 genomes share a homologous 7-kbp region immediately upstream of the gene encoding the major capsid protein, Arch Virol, 144, 2007, 10.1007/s007050050721
Mitchel, 2002, Sequence analysis of bacteriophage T4 DNA packaging/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases, Nucleic Acids Res, 30, 4009, 10.1093/nar/gkf524
Matsuzaki, 2000, Characterization of a novel Vibrio parahaemolyticus phage, KVP241, and its relatives frequently isolated from seawater, Microbiol Immunol, 44, 953, 10.1111/j.1348-0421.2000.tb02589.x
Matsuzaki, 2003, Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage S61542MR11, J Infect Dis, 187, 613, 10.1086/374001
Maniloff, 1998, Taxonomy of bacterial viruses: establishment of tailed virus genera and the order Caudovirales, Arch Virol, 143, 2051, 10.1007/s007050050442
Bernhardt, 2000, Genetic evidence that the bacteriophage S61542X174 lysis protein inhibits cell wall synthesis, Proc Natl Acad Sci USA, 97, 4297, 10.1073/pnas.97.8.4297
Bernhardt, 2000, The lysis protein E of S61542X174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis, J Biol Chem, 276, 6093, 10.1074/jbc.M007638200
Bernhardt, 2001, A protein antibiotic in the phage QS61538 virion: diversity in lysis target, Science, 292, 2326, 10.1126/science.1058289
Cao, 2000, Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth, Biochem Biophys Acta, 1474, 107, 10.1016/S0304-4165(00)00005-2
Hagens, 2004, Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage, Antimicrob Agents Chemother, 48, 3817, 10.1128/AAC.48.10.3817-3822.2004
Betley, 1985, Staphylococcal enterotoxin A is encoded by phage, Science, 229, 185, 10.1126/science.3160112
Bishai, 1988, Bacteriophage gene products that cause human diseases, 683
Kaneko, 1997, Panton-valentine leukocidin genes in a phage-like particle isolated from mitomycin C-treated Staphylococcus aureus V8 (ATCC 49775), Biosci Biotechnol Biochem, 61, 1960, 10.1271/bbb.61.1960
Kaneko, 1998, Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage ФPVL carrying Panton–Valentine leukocidin genes, Gene (Amst), 215, 57, 10.1016/S0378-1119(98)00278-9
Yamaguchi, 2000, Phage conversion of exfoliative toxin A production in Staphylococcus aureus, Mol Microbiol, 38, 694, 10.1046/j.1365-2958.2000.02169.x
Young, 1992, Bacteriophage lysis: mechanism and regulation, Microbiol Rev, 56, 430, 10.1128/mr.56.3.430-481.1992
Ackermann, 1998, Tailed bacteriophages: the order Caudovirales, Adv Virus Res, 51, 135, 10.1016/S0065-3527(08)60785-X
Wang, 2000, Holins: the protein clocks of bacteriophage infections, Annu Rev Microbiol, 54, 799, 10.1146/annurev.micro.54.1.799
Smith, 1982, Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics, J Gen Microbiol, 128, 307
Smith, 1983, Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets, and lambs, J Gen Microbiol, 129, 2659
Smith, 1987, Factors influencing the survival and multiplication of bacteriophages in calves and in their environment, J Gen Microbiol, 133, 1127
Smith, 1987, The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages, J Gen Microbiol, 133, 1111
Merril, 1996, Long-circulating bacteriophage as antibacterial agents, Proc Natl Acad Sci USA, 93, 3188, 10.1073/pnas.93.8.3188
Barrow, 1998, Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves, Clin Diagn Lab Immunol, 5, 294, 10.1128/CDLI.5.3.294-298.1998
Chibani-Chennoufi, 2004, In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy, Antimicrob Agents Chemother, 48, 2558, 10.1128/AAC.48.7.2558-2569.2004
Soothill, 1992, Treatment of experimental infections of mice with bacteriophages, J Med Microbiol, 37, 258, 10.1099/00222615-37-4-258
Soothill, 1994, Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa, Burns, 20, 209, 10.1016/0305-4179(94)90184-8
Ahmad, 2002, Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics, Med Hypotheses, 58, 327, 10.1054/mehy.2001.1522
Bogovazova, 1991, The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection, Zh Mikrobiol Epidemiol Immunobiol, 4, 5
Bogovazova, 1992, Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages, Zh Mikrobiol Epidemiol Immunobiol, 3, 30
Biswas, 2002, Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium, Infect Immun, 70, 204, 10.1128/IAI.70.1.204-210.2002
Cerveny, 2002, Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice, Infect Immun, 70, 6251, 10.1128/IAI.70.11.6251-6262.2002
Toro, 2005, Use of bacteriophages in combination with competitive exclusion to reduce Salmonella from infected chickens, Avian Dis, 49, 118, 10.1637/7286-100404R
Noble, 1998, Vol 3, 231
Hiramatsu, 2001, The emergence and evolution of methicillin-resistant Staphylococcus aureus, Trends Microbiol, 9, 486, 10.1016/S0966-842X(01)02175-8
Shimada, 2004, [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)], Jpn J Antibiot, 57, 213
Hiramatsu, 1997, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8
Chang, 2003, Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene, N Engl J Med, 348, 1342, 10.1056/NEJMoa025025
Kacica, 2004, Vancomycin-resistant Staphylococcus aureus–New York, 2004, MMWR (Morb Mortal Wkly Rep), 53, 322
Pillai, 2002, Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype, J Infect Dis, 186, 1603, 10.1086/345368
Wilson, 2003, Linezolid resistance in clinical isolates of Staphylococcus aureus, J Antimicrob Chemother, 51, 186, 10.1093/jac/dkg104
Ross, 2005, Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program, Diagn Microbiol Infect Dis, 52, 53, 10.1016/j.diagmicrobio.2004.12.013
Wills, 2005, Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model, Antimicrob Agents Chemother, 49, 1220, 10.1128/AAC.49.3.1220-1221.2005
O’Flaherty, 2005, Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals, Appl Environ Microbiol, 71, 1836, 10.1128/AEM.71.4.1836-1842.2005
Geier, 1973, Fate of bacteriophage lambda in non-immune germ-free mice, Nature (Lond), 246, 221, 10.1038/246221a0
Nakai, 1999, Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail, Dis Aquat Org, 37, 33, 10.3354/dao037033
Park, 2000, Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control, Appl Environ Microbiol, 66, 1416, 10.1128/AEM.66.4.1416-1422.2000
Nakai, 2002, Bacteriophage therapy of infectious diseases in aquaculture, Res Microbiol, 153, 13, 10.1016/S0923-2508(01)01280-3
Park, 2003, Bacteriophage control of Pseudomonas plecoglossicida infection in ayu Plecoglossus altivelis, Dis Aquat Org, 53, 33, 10.3354/dao053033
Leverentz, 2003, Biocontrol of Listeria monocytogenes on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin, Appl Environ Microbiol, 69, 4519, 10.1128/AEM.69.8.4519-4526.2003
Leverentz, 2004, Optimizing concentration and timing of a phage spray application to reduce Listeria monocytogenes on honeydew melon tissue, J Food Prot, 67, 1682, 10.4315/0362-028X-67.8.1682
Atterbury, 2003, Isolation and characterization of Campylobacter bacteriophages from retail poultry, Appl Environ Microbiol, 69, 4511, 10.1128/AEM.69.8.4511-4518.2003
Atterbury, 2003, Application of host-specific bacteriophages to the surface of chicken skin leads to a reduction in recovery of Campylobacter jejuni, Appl Environ Microbiol, 69, 6302, 10.1128/AEM.69.10.6302-6306.2003
Goode, 2003, Reduction of experimental Salmonella and Campylobacter contamination of chicken skin by application of lytic bacteriophages, Appl Environ Microbiol, 69, 5032, 10.1128/AEM.69.8.5032-5036.2003
Leverentz, 2001, Examination of bacteriophage as a biocontrol method for salmonella on fresh-cut fruit: a model study, J Food Prot, 64, 1116, 10.4315/0362-028X-64.8.1116
Payne, 2000, Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals, Clin Pharmacol Ther, 68, 225, 10.1067/mcp.2000.109520
Payne, 2001, Understanding bacteriophage therapy as a density-dependent kinetic process, J Theor Biol, 208, 37, 10.1006/jtbi.2000.2198
Kasman, 2002, Overcoming the phage replication threshold: a mathematical model with implications for phage therapy, J Virol, 76, 5557, 10.1128/JVI.76.11.5557-5564.2002
Payne, 2002, Evidence for a phage proliferation threshold?, J Virol, 76, 13123, 10.1128/JVI.76.24.13123-13124.2002
Payne, 2003, Pharmacokinetic principles of bacteriophage therapy, Clin Pharmacokinet, 42, 315, 10.2165/00003088-200342040-00002
Weld, 2004, Models of phage growth and their applicability to phage therapy, J Theor Biol, 227, 1, 10.1016/S0022-5193(03)00262-5
Navarre, 1999, Multiple enzymatic activities of the murein hydrolase from staphylococcal phage S6154211, J Biol Chem, 274, 15847, 10.1074/jbc.274.22.15847
Jado, 2003, Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model, J Antimicrob Chemother, 52, 967, 10.1093/jac/dkg485
Nelson, 2001, Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, Proc Natl Acad Sci USA, 98, 4107, 10.1073/pnas.061038398
Loeffler, 2001, Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase, Science, 294, 2170, 10.1126/science.1066869
Loeffler, 2003, Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia, Infect Immun, 71, 6199, 10.1128/IAI.71.11.6199-6204.2003
Loeffler, 2003, Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains, Antimicrob Agents Chemother, 47, 375, 10.1128/AAC.47.1.375-377.2003
Schuch, 2002, A bacteriolytic agent that detects and kills Bacillus anthracis, Nature (Lond), 418, 884, 10.1038/nature01026
Cheng, 2005, Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme, Antimicrob Agents Chemother, 49, 111, 10.1128/AAC.49.1.111-117.2005
Yoong, 2004, Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium, J Bacteriol, 186, 4808, 10.1128/JB.186.14.4808-4812.2004
Liu, 2004, Antimicrobial drug discovery through bacteriophage genomics, Nat Biotechnol, 22, 185, 10.1038/nbt932
Bernhardt, 2002, Breaking free: “protein antibiotics” and phage lysis, Res Microbiol, 153, 493, 10.1016/S0923-2508(02)01330-X
Panthel, 2003, Generation of Helicobacter pylori ghosts by ФX174 protein E-mediated inactivation and their evaluation as vaccine candidates, Infect Immun, 71, 109, 10.1128/IAI.71.1.109-116.2003
Clark, 2004, Bacterial viruses as human vaccines?, Expert Rev Vaccines, 3, 463, 10.1586/14760584.3.4.463
Jepson, 2004, Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle, Vaccine, 22, 2413, 10.1016/j.vaccine.2003.11.065
March, 2004, Genetic immunization against hepatitis B using whole bacteriophage lambda particles, Vaccine, 22, 1666, 10.1016/j.vaccine.2003.10.047
Montag, 1987, Receptor-recognizing proteins of T-even type bacteriophages. Constant and hypervariable regions and an unusual case of evolution, J Mol Biol, 196, 165, 10.1016/0022-2836(87)90519-5
Drexler, 1989, Receptor specificity of the Escherichia coli T-even type phage Ox2. Mutational alterations in host range mutants, J Mol Biol, 207, 797, 10.1016/0022-2836(89)90245-3
Drexler, 1991, Single mutations in a gene for a tail fiber component of an Escherichia coli phage can cause an extension from a protein to a carbohydrate as a receptor, J Mol Biol, 219, 655, 10.1016/0022-2836(91)90662-P